Stryker's Q2 2026 Earnings Preview: MedSurg Segment Concerns Amid Cyberattack and Revenue Miss

Stryker Corporation (SYK), set to announce its Q2 2026 results after the market closes on Thursday, July 30, faces investor scrutiny amid mixed earnings expectations and lingering effects from a March 2026 cyberattack. With a $125.3 billion market cap, the medical technology firm's MedSurg and Neurotechnology segment underperformance and Q1 2026 revenue shortfall ($6.02 billion vs. expectations) weigh on sentiment despite maintained annual EPS guidance of $14.90-$15.10.

Q2 2026 Expectations and Performance Analysis

■Analysts project adjusted EPS of $3.49, up 11.5% from $3.13 in the year-ago quarter.

■Q1 2026 results saw a 6.5% stock decline after reporting below-forecast revenue, with MedSurg and Neurotechnology sales at $3.21 billion falling short of targets.

■Orthopaedics segment growth of 6.3% to $2.81 billion offers partial offset but highlights uneven demand across core business lines.

Impact of Q1 2026 Results and Cyberattack Fallout

■The March 2026 cyberattack disrupted operations, compounding revenue misses and raising questions about operational resilience.

■While full-year guidance remains intact, underperformance in high-margin segments signals potential headwinds in a rising interest rate environment.

Global Positioning and Investor Sentiment

■SYK shares have lagged behind S&P 500's 20.1% gain and XLV ETF's 19.5% return over the past 52 weeks, with a -16.3% decline.

■2027 EPS forecast of $16.58 implies 10.7% annual growth but faces skepticism amid macroeconomic uncertainty and healthcare sector volatility.

Bora Yalın: Stryker's Q2 results serve as a bellwether for global medtech risk appetite. The MedSurg segment weakness underscores vulnerabilities in supply chain and demand shocks. Hedge fund positioning in such names amid renewed liquidity stress is noteworthy. SYK's trajectory, particularly regarding FDA regulations and global hospital spending trends, warrants close monitoring.